<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html><head>
<meta/><title></title></head><body><span></span>
<table>
<tbody>
<tr>
<td><br/><br/></td>
<!-- RIGHT LOGO -->
<td> </td>
</tr>
</tbody>
</table>
<div><br/>
<section>
<article><img/></article>
</section>
<p> <p><strong>Bagsværd, Denmark, 13 November 2023 </strong>— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.</p> <p>The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.</p> <p>Please find below a statement of such trading in shares issued by Novo Nordisk.</p> <table><tr><td><strong>1 </strong></td><td><strong>Details of the person discharging managerial responsibilities/person closely associated </strong></td></tr><tr><td>a)</td><td>Name of the Board member/Executive/Associated Person</td><td>David Moore</td></tr><tr><td><strong>2 </strong></td><td><strong>Reason for the notification</strong></td></tr><tr><td>a)</td><td>Position/status</td><td>Executive Vice President, head of Corporate Development</td></tr><tr><td>b)</td><td>Initial notification/Amendment</td><td>Initial notification</td></tr><tr><td><strong>3 </strong></td><td><strong>Details of the issuer</strong></td></tr><tr><td>a)</td><td>Name</td><td>Novo Nordisk A/S</td></tr><tr><td>b)</td><td>LEI</td><td>549300DAQ1CVT6CXN342</td></tr><tr><td><strong>4 </strong></td><td><strong>Details of the transaction(s)</strong></td></tr><tr><td>a)</td><td>Description of the financial instrument,<br/>type of instrument,</td><td>Shares<br/><br/></td></tr><tr><td> </td><td>Identification code</td><td>Novo Nordisk B DK0062498333</td></tr><tr><td>b)</td><td>Nature of the transaction</td><td>Other transaction (acquisition of shares in accordance with the recruitment package)</td></tr><tr><td>c)<br/><br/><br/><br/><br/><br/><br/><br/></td><td>Price(s) and volume(s)<br/><br/><br/><br/><br/><br/><br/><br/></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Price(s)</td><td>Volume(s)</td><td> </td></tr><tr><td> </td><td>DKK 0.00</td><td>18,636 shares</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td></tr><tr><td>d)</td><td>Aggregated information  <ul><li>Aggregated volume</li><li>Price</li></ul> </td><td><br/><br/>18,636 shares<br/>DKK 0.00</td></tr><tr><td>e)</td><td>Date of the transaction</td><td>2023-11-09</td></tr><tr><td>f)</td><td>Place of the transaction</td><td>Outside a trading venue</td></tr></table> <p> </p> <table><tr><td><strong>1 </strong></td><td><strong>Details of the person discharging managerial responsibilities/person closely associated </strong></td></tr><tr><td>a)</td><td>Name of the Board member/Executive/Associated Person</td><td>David Moore</td></tr><tr><td><strong>2 </strong></td><td><strong>Reason for the notification</strong></td></tr><tr><td>a)</td><td>Position/status</td><td>Executive Vice President, head of Corporate Development</td></tr><tr><td>b)</td><td>Initial notification/Amendment</td><td>Initial notification</td></tr><tr><td><strong>3 </strong></td><td><strong>Details of the issuer</strong></td></tr><tr><td>a)</td><td>Name</td><td>Novo Nordisk A/S</td></tr><tr><td>b)</td><td>LEI</td><td>549300DAQ1CVT6CXN342</td></tr><tr><td><strong>4 </strong></td><td><strong>Details of the transaction(s)</strong></td></tr><tr><td>a)</td><td>Description of the financial instrument,<br/>type of instrument,</td><td>Shares<br/><br/></td></tr><tr><td> </td><td>Identification code</td><td>Novo Nordisk B DK0062498333</td></tr><tr><td>b)</td><td>Nature of the transaction</td><td>Sale of shares</td></tr><tr><td>c)<br/><br/><br/><br/><br/><br/><br/><br/></td><td>Price(s) and volume(s)<br/><br/><br/><br/><br/><br/><br/><br/></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Price(s)</td><td>Volume(s)</td><td> </td></tr><tr><td> </td><td>DKK 701.52</td><td>8,217 shares</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td></tr><tr><td>d)</td><td>Aggregated information  <ul><li>Aggregated volume</li><li>Price</li></ul> </td><td><br/><br/>8,217 shares<br/>DKK 5,764,389.84</td></tr><tr><td>e)</td><td>Date of the transaction</td><td>2023-11-09</td></tr><tr><td>f)</td><td>Place of the transaction</td><td>Outside a trading venue</td></tr></table> <p><em>Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit </em><a><em>novonordisk.com</em></a><em>,</em> <a><em>Facebook</em></a><em>, </em><a><em>Instagram</em></a><em>, </em><a><em>X</em></a><em>, </em><a><em>LinkedIn</em></a><em> and</em> <a><em>YouTube</em></a><em>.</em></p> <p><strong>Contacts for further information</strong></p> <table><tr><td><strong>Media:</strong></td><td> </td></tr><tr><td><strong>Ambre James-Brown </strong><br/>+45 3079 9289<br/><a>abmo@novonordisk.com</a><br/><br/></td><td><strong>Elizabeth DeLuca (US)</strong><br/>+1 609 580 9868<br/><a>edel@novonordisk.com</a><br/><br/></td></tr><tr><td><strong>Investors:</strong></td><td> </td></tr><tr><td><strong>Daniel Muusmann Bohsen</strong><br/>+45 3075 2175 <br/><a>dabo@novonordisk.com</a><br/><br/></td><td><strong>Jacob Martin Wiborg Rode</strong><br/>+45 3075 5956<br/><a>jrde@novonordisk.com</a><br/><br/></td></tr><tr><td><strong>David Heiberg Landsted</strong> <br/>+45 3077 6915 <br/><a>dhel@novonordisk.com</a><br/><br/></td><td><strong>Mark Joseph Root (US)</strong> <br/>+1 848 213 3219<br/><a>mjhr@novonordisk.com</a><br/><br/></td></tr><tr><td><strong>Sina Meyer </strong><br/>+45 3079 6656 <a>azey@novonordisk.com</a><br/><br/></td><td><strong>Frederik Taylor Pitter </strong><br/>+45 3075 8259 <a>fptr@novonordisk.com</a><br/><br/></td></tr></table> <p>Company announcement No 76 / 2023</p> <p> </p> <p>
<strong>Attachment</strong>
</p>
<ul>
<li>
<a>CA231113-Insider-trading</a>
</li>
</ul>
</p>
<p><span>For more details about Novo Nordisk, please visit </span><span><a>www.novonordisk.com</a></span><span>; </span></p>
<p><em><span>Dear subscriber to Novo Nordisk press releases/company announcements<br/> We use your email address to send you news from Novo Nordisk. If you want to know how we comply with data privacy protection, you can read more here: <span><em><span><a>https://www.novonordisk.com/data-privacy-and-user-rights/privacy-notice-news-subscribe.html</a></span></em></span></span></em><span>.</span><span> </span><em><span>If you don’t want to subscribe anymore, </span><a>please go to novnordisk.com to unsubscribe.</a></em></p>
<p> </p>
<div> </div>
</div>
<img/></body></html>
